Shiseido (Japan)’s Dr. Jiro Kishimoto’s presentation is titled: “Autologous cell-based therapy for hair loss using dermal sheath cup cells.” Perhaps he will give some hints regarding how much further along Shiseido is in its development and enhancement of Replicel’s hair multiplication product?
There are a number of potentially interesting presentations focusing on the dermal papilla, prostaglandins, neogenesis, stem cells and hair genetics. One presentation has the strange title of: “Minoxidil and dutasteride drug tattooing for androgenetic alopecia”.
As has been mentioned numerous times by myself and many others over the past several years, Japan’s government is heavily promoting regenerative medicine in the rapidly aging country. One of the main ways it is doing so is via speeding up the usually lengthy and expensive clinical trial process (which is common in most developed countries).
Smart Hair Transplants
In the case of SHT, the process is autologous in nature. So clinical trials are possibly not required, or will be fairly short in duration if required.
Smart hair transplants theoretically provide unlimited donor hair. By isolating cells from the dermal papilla and then culturing and multiplying them, this procedure supposedly forms neopapillae. According to TissUse:
“Neopapillae are the precursors of hair follicles which have been shown to grow hair follicles under controlled conditions in vitro. Each of these neopapilla has the potential to form a brand new hair follicle.”